Efficacy and safety of belimumab in IgA nephropathy: real-world evidence - PubMed

4 hours ago

Belimumab, a monoclonal antibody, was evaluated for its efficacy and safety in treating IgA nephropathy (IgAN).
The study was a retrospective cohort analysis involving 206 IgAN patients, comparing 69 treated with belimumab against 137 on standard therapy.
Primary outcome was proteinuria remission, defined as a reduction in 24-hour urinary protein excretion or UPCR to <50% of baseline.
Results showed higher remission rates in the belimumab group: 59% vs 46% at 3 months, 77% vs 66% at 6 months, and 93% vs 80% at 12 months.
Newly diagnosed patients showed significantly higher remission rates at 3 and 6 months with belimumab.
Belimumab demonstrated comparable or superior proteinuria reduction in patients with baseline UPCR >600 mg/g and those on RAAS inhibitors.
No excess of common adverse events was observed in the belimumab group.
Conclusion: Belimumab is associated with higher proteinuria remission rates in IgAN without increased adverse events, suggesting it as a superior therapeutic option.

Hasty Briefsbeta